These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 9224607

  • 1. Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA.
    Kuwabara T, Warashina M, Tanabe T, Tani K, Asano S, Taira K.
    Nucleic Acids Res; 1997 Aug 01; 25(15):3074-81. PubMed ID: 9224607
    [Abstract] [Full Text] [Related]

  • 2. Comparison of activities between hammerhead ribozymes and DNA enzymes targeted to L6 BCR-ABL chimeric (b2a2) mRNA.
    Warashina M, Kuwabara T, Taira K.
    Nucleic Acids Symp Ser; 1997 Aug 01; (37):213-4. PubMed ID: 9586075
    [Abstract] [Full Text] [Related]

  • 3. Selective cleavage of bcr-abl chimeric RNAs by a ribozyme targeted to non-contiguous sequences.
    Pachuk CJ, Yoon K, Moelling K, Coney LR.
    Nucleic Acids Res; 1994 Feb 11; 22(3):301-7. PubMed ID: 8127665
    [Abstract] [Full Text] [Related]

  • 4. Investigating and improving the specificity of ribozymes directed against the bcr-abl translocation.
    James H, Mills K, Gibson I.
    Leukemia; 1996 Jun 11; 10(6):1054-64. PubMed ID: 8667643
    [Abstract] [Full Text] [Related]

  • 5. Extremely high and specific activity of DNA enzymes in cells with a Philadelphia chromosome.
    Warashina M, Kuwabara T, Nakamatsu Y, Taira K.
    Chem Biol; 1999 Apr 11; 6(4):237-50. PubMed ID: 10099134
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes).
    Wu Y, Yu L, McMahon R, Rossi JJ, Forman SJ, Snyder DS.
    Hum Gene Ther; 1999 Nov 20; 10(17):2847-57. PubMed ID: 10584930
    [Abstract] [Full Text] [Related]

  • 7. Specificity of novel allosterically trans- and cis-activated connected maxizymes that are designed to suppress BCR-ABL expression.
    Hamada M, Kuwabara T, Warashina M, Nakayama A, Taira K.
    FEBS Lett; 1999 Nov 12; 461(1-2):77-85. PubMed ID: 10561500
    [Abstract] [Full Text] [Related]

  • 8. Comparison of different ribozymes for efficient and specific cleavage of BCR/ABL related mRNAs.
    Lange W, Daskalakis M, Finke J, Dölken G.
    FEBS Lett; 1994 Jan 31; 338(2):175-8. PubMed ID: 8307177
    [Abstract] [Full Text] [Related]

  • 9. Allosterically controlled single-chained maxizymes with extremely high and specific activity.
    Kuwabara T, Hamada M, Warashina M, Taira K.
    Biomacromolecules; 2001 Jan 31; 2(3):788-99. PubMed ID: 11710033
    [Abstract] [Full Text] [Related]

  • 10. Activities of tRNA-embedded dimeric minizymes.
    Kuwabara T, Warashina M, Nakayama A, Ohkawa J, Taira K.
    Nucleic Acids Symp Ser; 1997 Jan 31; (37):307-8. PubMed ID: 9586122
    [Abstract] [Full Text] [Related]

  • 11. Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes.
    Kronenwett R, Haas R, Sczakiel G.
    J Mol Biol; 1996 Jun 21; 259(4):632-44. PubMed ID: 8683570
    [Abstract] [Full Text] [Related]

  • 12. Multi-unit anti-BCR-ABL ribozyme therapy in chronic myelogenous leukemia.
    Leopold LH, Shore SK, Reddy EP.
    Leuk Lymphoma; 1996 Aug 21; 22(5-6):365-73. PubMed ID: 8882949
    [Abstract] [Full Text] [Related]

  • 13. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
    Mendoza-Maldonado R, Zentilin L, Fanin R, Giacca M.
    Cancer Gene Ther; 2002 Jan 21; 9(1):71-86. PubMed ID: 11916246
    [Abstract] [Full Text] [Related]

  • 14. Ribozyme-mediated cleavage of the bcr/abl transcript expressed in chronic myeloid leukemia.
    Wright L, Wilson SB, Milliken S, Biggs J, Kearney P.
    Exp Hematol; 1993 Dec 21; 21(13):1714-8. PubMed ID: 8243570
    [Abstract] [Full Text] [Related]

  • 15. Improved specificity of ribozyme-mediated cleavage of bcr-abl mRNA.
    Kearney P, Wright LA, Milliken S, Biggs JC.
    Exp Hematol; 1995 Aug 21; 23(9):986-9. PubMed ID: 7543419
    [Abstract] [Full Text] [Related]

  • 16. Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias.
    Leopold LH, Shore SK, Newkirk TA, Reddy RM, Reddy EP.
    Blood; 1995 Apr 15; 85(8):2162-70. PubMed ID: 7718886
    [Abstract] [Full Text] [Related]

  • 17. Ex vivo effects associated with the expression of a bcr-abl-specific ribozyme in a CML cell line.
    Wright LA, Milliken S, Biggs JC, Kearney P.
    Antisense Nucleic Acid Drug Dev; 1998 Feb 15; 8(1):15-23. PubMed ID: 9512092
    [Abstract] [Full Text] [Related]

  • 18. Probing of the secondary structure of maxizymes.
    Zhou JM, Nakamatsu Y, Kuwabara T, Warashina M, Tanaka Y, Yoshinari K, Taira K.
    Nucleic Acids Symp Ser; 1999 Feb 15; (42):219-20. PubMed ID: 10780458
    [Abstract] [Full Text] [Related]

  • 19. Specificity of ribozymes against the bcr-abl mRNAs in vitro.
    James HA, Twomey CM, Mills KI, Gibson I.
    Biochem Soc Trans; 1996 Aug 15; 24(3):409S. PubMed ID: 8878953
    [No Abstract] [Full Text] [Related]

  • 20. Cleavage of BCR/ABL mRNA by synthetic ribozymes--effects on the proliferation rate of K562 cells.
    Lange W.
    Klin Padiatr; 1995 Aug 15; 207(4):222-4. PubMed ID: 7564157
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.